Aratana announces positive top-line results from AT-001 pivotal field study in dogs
Aratana announced positive results from its pivotal field study of AT-001 (Grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores statistically significant compared to placebo. December 18, 2014